About Us

Since its founding in 2000, MacroGenics has focused on applying its world-class antibody capabilities to discover, develop and deliver to patients novel biologics for the treatment of cancer, autoimmune disorders and infectious diseases.

Our team of 135 dedicated individuals is committed to apply breakthrough science to create life-changing medicines. As an example, our lead autoimmune product candidate, teplizumab, is thought to reprogram the immune system to re-establish the lost immune balance that occurs in autoimmune diseases such as type 1 diabetes. If successful, this approach would represent a paradigm shift in the management of a disease for which there has been no new treatment since the introduction of insulin in the 1920’s.

Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms:

• Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule;
• Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy; and
• Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells.

Research & Development Process at MacroGenics

The illustration below provides an overview of the research and development process at MacroGenics.  By maintaining in-house capabilities across the entire product development spectrum, we reduce our reliance on external contractors and better anticipate downstream development requirements. Furthermore, our highly collaborative approach to product development facilitates the rapid transition of programs through the development process. 
 


Product Pipeline Summary

MacroGenics has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. 

In oncology, MacroGenics initiated clinical development of MGAH22 in August 2010.  MGAH22 is the first Fc-modified anti-cancer mAb produced from the company’s proprietary Fc optimization technology and targets tumors that over-express the HER2 oncoprotein, potentially including breast, bladder, gastric, prostate and pancreatic.  In mid-2011, MacroGenics began clinical development of its second anti-cancer mAb, MGA271, which recognizes a novel target (B7-H3), which is expressed on several solid tumor types.  MGA271 is a humanized, Fc-optimized mAb that is being studied for the treatment of multiple solid tumors, potentially including prostate, renal and pancreatic cancers as well as melanomas.  MacroGenics’ earlier stage oncology pipeline includes multiple programs for which the company expects to select clinical development candidates over the next several years.

The company’s lead autoimmune program, teplizumab, is an anti-CD3 antibody being developed for the prevention and treatment of early onset type 1 diabetes.  In June 2011, MacroGenics announced the publication in The Lancet of results from Protégé, a Phase 3 clinical study of teplizumab in type 1 diabetes. Exploratory, post-hoc analyses suggest that teplizumab, an anti-CD3 monoclonal antibody, when used in a full dose regimen may preserve C-peptide and increase the percentage of patients requiring very low doses of insulin compared to those on placebo. In addition, these analyses identified certain subpopulations to be studied in future trials.

MacroGenics is also pursuing development of its own proprietary molecules for the treatment of inflammatory disease.

MacroGenics’ infectious disease portfolio includes several antibody-based therapeutics for the treatment of infectious diseases from pathogens, including Dengue, smallpox and H5N1.

View full Product Pipeline